Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2701 - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Francesco Giusti


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


F. Giusti1, C. Martos1, E. Crocetti2, N. Dimitrova1, G. Randi1, L. Neamtiu1, R.N. Carvalho1, T. Dyba1, M. Flego1, N. Nicholson1, M. Bettio1

Author affiliations

  • 1 Directorate F Health, Consumers And Reference Materials, Health In Society Unit, European Commission – Joint Research Centre, 21027 - Ispra/IT
  • 2 Health Science, University of Florence, 50121 - Florence/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2701


The basic scope of population-based cancer registries (CRs) is to collect data that enable computation of cancer incidence. In addition to this, nowadays most registries can provide more extensive information such as data on stage and treatment, which could be used to assess and compare different care pathways. The current analysis reports on treatment by stage patterns for female breast cancer in Europe.


Data from CRs included in the European Cancer Information System (ECIS) and having submitted data on stage and treatment for the ENCR-JRC project were analysed. Proportion of cases by treatment type: surgery (SG), radiotherapy (RT), systemic therapy (ST), by stage, age, period and region were calculated.


829,247 cases from 20 CRs were analysed. Treatment for stage I (UICC TNM) patients aged 19-74 in 1999-2005 was SG alone (22%), SG+ST (13%) SG+RT (31%), SG+RT+ST (32%). SG alone decreased to 18%, while SG+RT+ST rose to 37% in 2006-13. High variability was observed: in Eastern Europe SG alone was 31%, SG+ST 17%, SG+RT 24%, SG+RT+ST 23% in 2006-13, in Western Europe SG alone was 12%, SG+ST 13%, SG+RT 31%, SG+RT+ST 43%. For age 75+ in 1999-2005 SG (37%) and SG+ST (20%) were higher than in 19-74 patients, while SG+RT (17%) and SG+RT+SG (15%) were lower. SG decreased to 31%, SG+RT+ST rose to 20% in 2006-13. Untreated patients were 3% in both periods. For the regional comparison, in 2006-13 SG alone was 50% in Eastern Europe vs 25% in Western Europe; SG+RT+ST was 9% in Eastern Europe, 24% in Western Europe. In 2006-13 for younger stage IV patients SG alone was 7%, ST alone 29%, SG+ST 18%, SG+RT+ST 14%, no treatment 9%. For 75+ patients SG was 11%, ST 30%, SG+ST 12%, SG+RT+ST 7%, no treatment 15%.


Variability in treatment patterns was observed by stage, age, period and region. Clinical information from CRs should be routinely used to monitor clinical care patterns, according to national and international recommendations, to compare levels of compliance and inform policy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

European Commission.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.